Trial Profile

A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
Indications Juvenile rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Sponsors Hope Biosciences

07 Jan 2026 Planned End Date changed from 1 Dec 2027 to 2 Jan 2026.
07 Jan 2026 Planned primary completion date changed from 1 Dec 2027 to 2 Jan 2026.
07 Jan 2026 Status changed from recruiting to withdrawn prior to enrolment. Reason the study was stopped: In the time that the site has been active, there have been 0 patients enrolled despite our best efforts. It is clear that it is not feasible to conduct this study at this time; therefore, we have withdrawn this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com